Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1ZAW4
|
|||
| Drug Name |
DYN101
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Congenital structural myopathy [ICD-11: 8C72.0] | Phase 1/2 | [1] | |
| Company |
Dynacure Jenkintown, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNM2 messenger RNA (DNM2 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04033159) A Phase 1/2 Trial on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of DYN101 in Patients >= 16 Years of Age With Centronuclear Myopathies Caused by Mutations in DNM2 or MTM1. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.